Company intelligence / Profile preview
XVir Therapeutics
Munich, Bavaria, Germanyxvir.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The lead candidate, XVir-N-31, is in preclinical development for muscle invasive bladder carcinoma, utilizing novel delivery approaches with hepatic stellate cells for improved safety and tumor targeting.
- Therapeutic areas
- NephrologyOncology
- Modalities
- Oncolytic virus therapy
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on XVir Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XVir Therapeutics.